Duchenne Muscular Dystrophy (DMD): Competitive Landscape to 2026

Table of Contents
1. Preface 2
1.1 Table of Contents 2
1.2 Abbreviations 3
1.3 Related Reports 4
2. Executive Summary 5
2.1 Key Findings 6
2.2 Key Events 7
3. Introduction 8
3.1 Report Scope 9
3.2 Disease Definition and Epidemiology Overview 11
4. Pipeline Assessment 14
4.1 Pipeline Overview 15
4.2 Pipeline Products by Region/Country 17
4.3 Pipeline Products by Molecule Type and Target 18
4.4 Drug Review Designations 19
4.5 Products in Clinical Development 20
5. Clinical Trial Assessment 22
5.1 Clinical Trials Overview 23
5.2 Top Sponsors of Clinical Trials in DMD 24
5.3 Trial Breakdown by Region 26
5.4 Trials Success Rate 27
5.5 Therapy Area Perspective 28
5.6 Enrollment Analytics 29
6. Commercial Assessment 32
6.1 Leading Marketed Products 33
6.2 Current & Future Players 34
7. Competitor Landscape Analysis (2016-2026) 35
7.1 Events and Segmentation Overview 36
7.2 US 37
7.3 5EU and Japan 38
8. Appendix 39
8.1 Sources 40
8.2 Methodology 42
8.3 Key Events Included in the Analysis 43
8.4 About the Authors 44
8.5 About GlobalData 47
8.6 Contact Us 48
8.7 Disclaimer 49